Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Ardea Biosciences, Inc. (RDEA)
|
Add to portfolio |
|
|
|
| Price: |
$31.96
| | Metrics |
| OS: |
36.9
|
M
| |
-55
|
% ROE
|
| Market cap: |
$1.18
|
B
| |
-95
|
% ROIC
|
|
Net cash:
|
$213
|
M
| |
$5.77
|
per share
|
|
EV:
|
$965
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($112)
|
M
| |
|
|
|
EBIT
|
($112)
|
M
| |
|
|
| EPS |
($3.92)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 |
| Revenues | 7.3 | 27.4 | 22.9 | 0.3 | 3.1 | 0.1 | 0.3 | 11.5 |
| Revenue growth | -73.4% | 19.5% | 7444.7% | -90.2% | 4198.6% | -71.8% | -97.8% | 49.1% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 11.9 | 7.6 | 2.7 | 3.6 | 5.7 |
| Gross profit | 7.3 | 27.4 | 22.9 | -11.6 | -4.5 | -2.6 | -3.4 | 5.8 |
| Gross margin | 100.0% | 100.0% | 100.0% | -3821.4% | -144.5% | -3613.9% | -1322.7% | 50.7% |
| Research and development | 74.4 | 52.1 | 42.2 | | | | | |
| General and administrative | 19.5 | 16.5 | 10.7 | 11.9 | 7.6 | 2.7 | 3.0 | 4.8 |
| EBIT | -86.7 | -41.1 | -30.0 | -56.5 | -27.6 | -2.7 | -3.2 | -16.3 |
| EBIT margin | -1186.3% | -150.1% | -130.6% | -18577.3% | -890.9% | -3813.9% | -1268.6% | -141.8% |
| Pre-tax income | -86.6 | -41.6 | -30.9 | -55.0 | -25.1 | -0.4 | -3.2 | -16.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -86.6 | -41.6 | -30.9 | -55.1 | -25.3 | -0.6 | -3.4 | -17.0 |
| Net margin | -1185.2% | -151.8% | -134.6% | -18110.2% | -817.8% | -843.1% | -1337.6% | -147.2% |
| |
| Diluted EPS | ($3.26) | ($1.91) | ($1.70) | ($3.79) | ($2.55) | ($0.07) | ($0.37) | ($2.24) |
| Shares outstanding (diluted) | 26.5 | 21.8 | 18.2 | 14.5 | 9.9 | 9.3 | 9.1 | 7.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|